Literature DB >> 20852936

Case report: Long-term outcome post-heart transplantation in a woman with Fabry's disease.

Flavia Verocai1, Joe Thomas Clarke, Robert M Iwanochko.   

Abstract

Fabry's disease is an X-linked recessive disorder that results from the deficiency of alpha-galactosidase A and causes the accumulation of globotriaosylceramide (Gb3) in different tissues. It leads to a rare form of cardiomyopathy which may be complicated by end-stage heart failure and need to heart transplant. Our group described the first case of heart transplant in a woman with cardiomyopathy secondary to Fabry's disease about 12 years ago. There was uncertainty in regards to the possibility of recurrence of the disease as previously documented in kidney transplant recipients and long-term outcomes. In this report, 14 years after transplant, this woman is still alive and there is no evidence of Fabry's disease in any of the endomyocardial biopsies. Heart transplantation can be recommended for Fabry's patients with end-stage cardiomyopathy.

Entities:  

Mesh:

Year:  2010        PMID: 20852936     DOI: 10.1007/s10545-010-9194-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Kidney transplantation in patients with Fabry disease.

Authors:  Markus Cybulla; Kerstin Nanette Walter; Andreas Schwarting; Raffaelle Divito; Sandro Feriozzi; Gere Sunder-Plassmann
Journal:  Transpl Int       Date:  2009-01-22       Impact factor: 3.782

2.  Cardiac transplantation for Fabry's disease.

Authors:  W J Cantor; P Daly; M Iwanochko; J T Clarke; R J Cusimano; J Butany
Journal:  Can J Cardiol       Date:  1998-01       Impact factor: 5.223

3.  Clinical benefit of enzyme replacement therapy in Fabry disease.

Authors:  F Breunig; F Weidemann; J Strotmann; A Knoll; C Wanner
Journal:  Kidney Int       Date:  2006-04       Impact factor: 10.612

4.  Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria.

Authors:  Julia Kleinert; Peter Kotanko; Marco Spada; Severo Pagliardini; Eduard Paschke; Karl Paul; Till Voigtländer; Manfred Wallner; Reinhard Kramar; Hans-Krister Stummvoll; Christoph Schwarz; Sabine Horn; Herwig Holzer; Manuela Födinger; Gere Sunder-Plassmann
Journal:  Transpl Int       Date:  2008-10-24       Impact factor: 3.782

5.  Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Authors:  A Mehta; M Beck; P Elliott; R Giugliani; A Linhart; G Sunder-Plassmann; R Schiffmann; F Barbey; M Ries; J T R Clarke
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

6.  Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

Authors:  D A Hughes; P M Elliott; J Shah; J Zuckerman; G Coghlan; J Brookes; A B Mehta
Journal:  Heart       Date:  2007-05-04       Impact factor: 5.994

7.  Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era.

Authors:  A Karras; P De Lentdecker; M Delahousse; M Debauchez; L Tricot; M Pastural; P Bruneval; L Zemoura; J-P Duong Van Huyen; O Lidove
Journal:  Am J Transplant       Date:  2008-06       Impact factor: 8.086

8.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

Review 9.  Cardiac challenges in patients with Fabry disease.

Authors:  F Weidemann; A Linhart; L Monserrat; J Strotmann
Journal:  Int J Cardiol       Date:  2009-08-31       Impact factor: 4.164

10.  Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.

Authors:  Cristina Chimenti; Maurizio Pieroni; Emanuela Morgante; Daniela Antuzzi; Andrea Russo; Matteo Antonio Russo; Attilio Maseri; Andrea Frustaci
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.